Comments
Celgene Corp said on Monday it would pay about $9 billion in cash to acquire the rest of Juno Therapeutics Inc and gain access to Juno's experimental gene therapy to treat cancer.
The $9 billion represents an offer $87 per share to Juno's shareholders and the deal, agreed by both boards, is expected to close in the first quarter of 2018.The acquisition will add JCAR017, Juno's experimental treatment for a type of blood cancer, to Celgene's lymphoma program.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.